Short-term treatment satisfaction with Cosentyx for hidradenitis suppurativa in Saudi Arabia

Survey Assessing Prospective Patient's Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Cosentyx (Secukinumab) in Routine Clinical Practice in Saudi Arabia: ILLUMINATE-SA

This will see if adults in Saudi Arabia with moderate-to-severe hidradenitis suppurativa who start Cosentyx are satisfied with its convenience, safety, and effectiveness after 24 weeks.

Quick facts

• Study type: Observational
• Enrollment: 77 (estimated)
• Ages: 18 Years to 99 Years
• Sex: All
• Sponsor: Novartis (Industry-sponsored)
• Drugs / interventions: Secukinumab
• Locations: 4 sites (Riyadh, SAU and 3 other locations)
• Trial ID: NCT06785779 on ClinicalTrials.gov

What this trial studies

This is a 24-week, single-arm, prospective observational study of adults with moderate-to-severe hidradenitis suppurativa treated in routine clinical practice in Saudi Arabia. Secukinumab-naive patients who begin Cosentyx will have data collected at baseline and at 24 weeks from electronic medical records and patient-reported questionnaires (TSQM, DLQI, and NPRS-11). The primary focus is patient-reported treatment satisfaction (convenience, perceived safety, perceived effectiveness, and global satisfaction) measured by the TSQM at week 24. The design follows standard-of-care visits and allows concurrent antibiotics or surgery as clinically indicated.

Who should consider this trial

Good fit: Adults (≥18 years) in Saudi Arabia with confirmed active moderate-to-severe HS who are secukinumab-naive and agree to complete questionnaires are eligible.

Not a fit: Patients under 18, those with prior biologic or JAK inhibitor use, or those unwilling to complete the informed consent and questionnaires are unlikely to benefit from participation.

Why it matters

Potential benefit: If positive, the results could help patients and clinicians understand real-world satisfaction with Cosentyx and support shared treatment decisions for HS.

How similar studies have performed: Secukinumab has been studied in hidradenitis suppurativa with some clinical trial data supporting effectiveness, but there are limited published real-world patient-satisfaction data.

Eligibility criteria

Inclusion Criteria:

1. Male or Female adult patients ≥18 years of age at the time of data collection.
2. Patient with a confirmed diagnosis of active moderate to severe HS.
3. Secukinumab naive patients (first dose to coincide within one month of the signature of the informed consent) as per locally approved label.
4. Patients can be using antibiotics or have undergone surgery as per routine clinical practice.
5. Patients agree to sign an informed consent form (ICF) to be able to complete the questionnaires.

Exclusion Criteria:

1. Patients not fulfilling any of the above-mentioned inclusion criteria.
2. Patient's refusal to be included in the study or refusal to sign the ICF.
3. A history of off-label indication uses of biological treatment or JAK inhibitor.

Where this trial is running

Riyadh, SAU and 3 other locations

• Novartis Investigative Site — Riyadh, Sau, Saudi Arabia (Recruiting)
• Novartis Investigative Site — Jeddah, Saudi Arabia (Recruiting)
• Novartis Investigative Site — Jeddah, Saudi Arabia (Recruiting)
• Novartis Investigative Site — Riyadh, Saudi Arabia (Recruiting)

Study contacts

• Study coordinator: Novartis Pharmaceuticals

Conditions Hidradenitis Suppurativa; HS; secukinumab; NIS; Saudi Arabia